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Introduction: In September 2015, Nigeria was removed from the list of polio-endemic countries after
more than 12 months had passed since the detection of last wild poliovirus case in the country on 24
July 2014. We are presenting here a report of two polio seroprevalence surveys conducted in
September 2013 and October 2014, respectively, in the Kano state of northern Nigeria.
Methods: Health facility based seroprevalence surveys were undertaken at Murtala Mohammad
Specialist Hospital, Kano. Parents or guardians of children aged 6–9 months, 36–47 months, 5–9 years
and 10–14 years in 2013 and 6–9 months and 19–22 months (corresponding to 6–9 months range at
the time of 2013 survey) in 2014 presenting to the outpatient department, were approached for partic-
ipation, screened for eligibility and asked to provide informed consent. A questionnaire was administered
and a blood sample collected for polio neutralization assay.
Results: Among subjects aged 6–9 months in the 2013 survey, seroprevalence was 58% (95% confidence
interval [CI] 51–66%) to poliovirus type 1, 42% (95% CI 34–50%) to poliovirus type 2, and 52% (95% CI
44–60%) to poliovirus type 3. Among children 36–47 months and older, seroprevalence was 85% or higher
for all three serotypes. In 2014, seroprevalence in 6–9 month infants was 72% (95% CI 65–79%) for type 1,
59% (95% CI 52–66%) for type 2, and 65% (95% CI 57–72%) for type 3 and in 19–22 months, 80% (95% CI
74–85%), 57% (49–63%) and 78% (71–83%) respectively. Seroprevalence was positively associated with
history of increasing oral poliovirus vaccine doses.
Conclusions: There was significant improvement in seroprevalence in 2014 over the 2013 levels indicat-
ing a positive impact of recent programmatic interventions. However the continued low seroprevalence
in 6–9 month age is a concern and calls for improved immunization efforts to sustain the polio-free
Nigeria.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Since the World Health Assembly resolved in 1988 to eradicate
poliomyelitis globally [1], great strides have been made towards
achieving this goal. The overall incidence of poliomyelitis has
declined by more than 99% [2], wild poliovirus (WPV) type 2 has
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have passed since the last case of WPV type 3 was detected in
November 2012 in Nigeria [2,4].
Nigeria has been removed from the list of polio endemic coun-
tries by World Health Organization (WHO) after more than
12 months having passed since the detection of the last case of
WPV type 1 in the country having onset of paralysis on 24 July
2014 [5]. Only two countries, Pakistan and Afghanistan remain
endemic for WPV type 1. The main challenges to eradicating
poliomyelitis in the remaining endemic countries include limited
access to children in security compromised areas and inadequate
service delivery of oral poliovirus vaccine (OPV) [6,7].
Nigeria has been polio-endemic all along and achieved the mile-
stone of interrupting poliovirus transmission after a long fought
battle. Historically, Nigeria has been reporting a large proportion
of global polio case burden. A consistent downward trend in the
number of confirmed WPV cases started in 2012, leading to the
current polio-free status. As per WHO data (as of 05 May 2016),
Nigeria had 53 cases of confirmed WPV1 in 9 States in 2013, 6
cases in 2 States in 2014, and no cases in 2015 [8]. Recent detection
of WPV1 cases in Borno state is under investigation.
Besides WPV transmission, Nigeria has the problem of persis-
tent transmission of circulating vaccine-derived poliovirus type 2
(cVDPV2) [9–11]. Cases of cVDPV2 detected increased from 4 in
2013 to 30 in 2014. Bivalent (types 1 and 3) OPV (bOPV) was used
in most Supplementary Immunization Activities (SIAs) covering
the 11 high-risk northern Nigerian states during this period. The
associated decline in type 2 immunity is likely to have caused
the increase in cVDPV2 cases in 2014. However, a number of triva-
lent OPV (tOPV) SIA rounds conducted since August 2014, as well
as targeted campaigns with inactivated polio vaccine (IPV), are
likely to have improved levels of immunity to type 2 poliovirus
and subsequent decline in cVDPV2. In 2015, one case of cVDPV2
was detected in the country in the Federal Capital Territory (FCT)
Abuja and this year in 2016, one case of VDPV2 has been reported
from Jigawa state and one environmental isolation from Borno
state of Nigeria.
Poliovirus transmission in Nigeria in the last two years preced-
ing the last case has largely been confined to NorthWest and North
East zones, and most cases having been reported from Kano, Borno
and the Yobe states. Kano State, the most populous in northern
Nigeria with 44 LGAs, has had the most intractable transmission
of poliovirus in the region. Even when there was a persistent
decline in the number of polio cases in Nigeria, Kano reported a rel-
atively large number of cases: 15 WPV1 cases in 2013 and 5 WPV1
and 10 cVDPV2 cases in 2014. Within Kano, Kano Metropolitan
Area (KMA), the urban area comprising of 8 very high risk local
government areas (LGAs), has always been categorized as very high
risk for polio.
We conducted seroprevalence surveys in KMA to measure polio
seroprevalence levels in 2013 and then repeated in 2014 in the dif-
ferent age groups of interest. In addition, we evaluated factors
probably associated with seroprevalence levels. The data were
intended for assessment of program performance and to guide
future actions. An earlier seroprevalence carried out in this area
in 2011 was published in Vaccine [12], and preliminary data sum-
marized in JID supplement in 2016 [13].
2. Methods
2.1. Study design and its rationale
A health facility-based cross-sectional design was used in both
the surveys. Experience of 2011 survey had shown that the sample
representation from 8 LGAs of KMA was quite proportionate to the
population. Both the vaccine acceptors and refusers had partici-pated. Moreover, health facility based was an operational advan-
tage in this area with considerable security risk for field operations.
Seroprevalence levels were assessed in four age groups in the
2013 survey: 6–9 months, 36–47 months, 5–9 years, and 10–
14 years. Seroprevalence was found to be quite low in 6–9 month
group, possibly attributed to a dip in the quality of SIAs due to kill-
ing of polio vaccinators in Kano during that period [14]. So it was
decided to do a follow-up survey in 2014 in 6–9 month and 19–
22 month age groups, the latter corresponding to 6–9 month
cohort at the time of 2013 survey.
2.2. Objectives of 2014 survey were
(1) To assess seroprevalence in 6–9 month olds and compare it
with levels in 2013, as an indicator of recent program
quality.
(2) To demonstrate improvement in seroprevalence in 19–
22 month olds, birth cohort that was aged 6–9 months at
the time of 2013 survey.
2.3. Selection of the study area
Kano state and KMA within the state were selected for assess-
ment of seroprevalence primarily due to the high incidence of
poliomyelitis cases in recent years. KMA comprises eight local gov-
ernment areas (LGAs): Kano Municipal, Fagge, Nassarawa, Dala,
Gwale, Tarauni, Ungogo, and Kumbotso. The location of Kano state
and KMA are indicated in the map of northern Nigeria, see previous
publication 12.
2.4. Selection of study site
Murtala Mohammad Specialist Hospital (MMSH) was selected
as the study site because it is the largest hospital in KMA. This pub-
lic sector hospital has a very high turnover of patients in the pedi-
atrics outpatient department (OPD). Patients come from a wide
catchment area including our area of interest i.e. the 8 LGAs of
KMA, with a total population of around 3.7 million.
2.5. Sample size
For the 2013 survey, the actual seroprevalence from the 2011
survey was used for sample size calculations. A total of 600 chil-
dren were required to be enrolled: 150 from each of the four age
groups. For the 2014 follow-up survey, due to much lower sero-
prevalence in 2013, a somewhat larger sample size was needed
to maintain the same precision of ±7.5% and 95% confidence. Using
the type 3 seroprevalence for the 6–9 month age group of 51% from
the 2013 survey, sample size of 171 was arrived at. It was inflated
to 180 per age group to account for withdrawal and inability to
draw sufficient quantity of blood, the total sample size used for
two age groups was 360.
2.6. Eligibility criteria
Infants fulfilling age requirement and residing for at least one
month in KMA with consenting care-givers were eligible to partic-
ipate, except those with (a) contraindication to venipuncture; (b)
serious acute illness requiring hospitalization; or (c) diagnosed or
suspected congenital immunodeficiency disorder in the subject
or an immediate family member.
2.7. Enrollment and survey procedures
Enrollment for the 2013 survey was done between 12 Septem-
ber and 2 October. Corresponding period for the 2014 survey was
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procedures were similar for the two surveys. Parents and guar-
dians of patients visiting the pediatric OPD of MMSH were
approached for participation of their infant/child in this survey. Ini-
tial screening for age and area of residence was done by a study
staff in the OPD. The physician in the study clinic explained the
study to the parents or guardians and assessed children for inclu-
sion criteria. After obtaining informed consent of caretakers and
assent from older children, weight and length/height were mea-
sured, immunization history was taken and the questionnaire
was completed. Regulations governing research involving human
subjects were followed throughout the course of the study.
2.8. History of Routine and SIA doses
As per Nigeria’s national policy, routine immunization (RI)
doses of tOPV (switched to bOPV since April 2016) were recom-
mended to be administered at birth, 6, 10 and 14 weeks, and mul-
tiple SIAs were implemented in the Kano area every year with
bOPV or tOPV, wherein all children up to 5 years old were expected
to receive an additional dose every time irrespective of their
immunization status. As a result, the study participants were eligi-
ble for a maximum of 4 RI doses and a variable number of SIA doses
depending on the age of the child and completeness of coverage in
SIA. Overall going by the SIA calendar, 6–9 month old infants could
have received a maximum of 6–8 bOPV doses through SIAs since
birth in 2013 survey and 6 bOPV doses and 1 tOPV dose in 2014
survey.
2.9. Blood collection and antibody testing procedures
One milliliter of blood was collected through venipuncture. Sera
were shipped to the Centers for Disease Control and Prevention
(CDC) in Atlanta. Sera were tested in triplicate for levels of neutral-
izing antibody titers against poliovirus types 1, 2, and 3, respec-
tively, using modified micro-neutralization assays, using
dilutions of 1:8–1:1024 [15,16]. For seroprevalence, antibody titers
P1:8 were regarded as positive (i.e., detectable titer).
2.10. Definitions
History of doses received by the study participants was primar-
ily based on verbal recall because immunization card/other docu-
mentary evidence were not available with most parents. RI and
SIA doses were recorded separately and added to arrive at the total
doses. Doses were included regardless of how close they were in
time to other doses except when the last dose was on the day of
blood sample collection. Nutritional status was measured using
height and weight. Data were compared to the standard distribu-
tion of a reference population using WHO Anthro software [17].
The reference population was the WHO Child Growth Standards
based on the WHO Multicenter Growth Reference Study (MGRS)
[18]. Categories of malnutrition were based on standard deviation
(SD) units (z-scores) below the mean of the reference population.
These categories were defined as normal (<2 SD), severe to moder-
ate (2.0–2.99 SD) and extreme (P3 SD).
2.11. Data management and statistical analysis
Questionnaires were double-entered into an initial database
using CSPro software version 5.0 [19]. Data analysis was done
using R (R Foundation) versions 3.0.2 (2013) and 3.1.1 (2014)
[20]. Chi-square tests were used to assess the association between
dichotomous predictors and seroprevalence. The Cochrane-
Armitage test for trend was used to test for trend in seroprevalence
across sub-groups of ordinal variables. Logistic regression was usedto estimate adjusted odds ratios and to assess the association of
other risk factors (such as gender, education level, and nutrition)
with seroprevalence by the number of OPV doses received in
infants 6–9 months of age. All risk factors were considered in the
initial models, and covariates with type III p-value <0.10 were
included in the final models.3. Results
3.1. Final study sample and distribution
The final sample consisted of 602 subjects for the 2013 survey
(4 age groups) and 363 subjects for the 2014 survey (2 age groups).
Subjects from all eight LGAs in KMA were included and the distri-
bution was found to be approximately proportionate to the total
population of the LGAs.
3.2. Characteristics of study subjects
The demographic characteristics of the participants from both
surveys are shown in Table 1. Two younger age groups from the
2013 survey and both age groups from the 2014 survey have been
analyzed in greater detail: Nutritional indices and data on the
number of OPV doses received are shown only for these age
groups.
There was a small imbalance in the proportion of male to
female infants in the 6–9 month age group, with 60% and 55% of
the subjects being male in the 2013 and 2014 surveys respectively.
Subsequent analyses showed that there was no difference in sero-
prevalence levels between males and females and that gender was
not a significant predictor of seropositivity.
3.3. Seroprevalence in 2013
Overall seroprevalence was low in the 6–9 month age group.
The seroprevalence levels plateaued in the 36–47 month age
group; with only minor gains in the 5–9 year and 10–14 year age
groups (Table 2).
Among subjects aged 6–9 months, seroprevalence was 58% (95%
confidence interval [CI] 51–66%) to poliovirus type 1, 42% (95% CI
34–49%) to poliovirus type 2, and 52% (95% CI 44–60%) to polio-
virus type 3. Among subjects aged 36–47 months, the seropreva-
lence was 93% (95% CI 88–96%) to poliovirus type 1, 85% (95% CI
78–90%) for poliovirus type 2, and 87% (95% CI 81–92%) to polio-
virus type 3. Seroprevalence was significantly higher in the 36–
47 months group for each type as compared to 6–9 months group
(p < 0.0001 for all three serotypes).
3.4. Trends in seroprevalence over time
Table 3 shows the seroprevalence and 95% confidence intervals
for the 6–9 month age group in 2013 and 2014 serosurveys. The
seroprevalence levels in this age group improved in 2014, from
58% in 2013 to 72% (95% CI 65–79%) in 2014 for type 1
(p = 0.009), from 42% to 59% (95% CI 52–66%) for type 2
(p = 0.001), and from 52% to 65% (95% CI 57–72%) for type 3
(p = 0.016).
Comparison of the seroprevalence levels for the 6–9 month
cohort of 2013 becoming 19–22 months old in the 2014 survey;
is shown in Fig. 1. An increase in seroprevalence to the tune of
23%, 16% and 27% was seen for the three poliovirus types: from
58% for infants 6–9 months old in 2013 to 81% for children 19–
22 months old in 2014 (95% CI 75–87%) for type 1 (p < 0.001), from
41% to 57% (95% CI 50–64%) for type 2 (p = 0.004), and from 52% to
79% (95% CI 72–84%) for type 3 (p < 0.001). Even in 2014, type 2
Table 1
Demographic and other attributes of study population, Kano Metropolitan Area, Northern Nigeria, 2013 and 2014.
2013 2014
6–9 months 36–47 months 5–9 years 10–14 years 6–9 months 19–22 months
N % N % N % N % N % N %
Total 154 143 151 154 183 184
Gender
Female 61 39.6 71 49.7 61 40.4 77 50.0 82 44.8 93 50.5
Male 93 60.4 72 50.4 90 59.6 77 50.0 101 55.2 91 49.5
Mother’s education
Primary or less 78 50.7 81 56.6 97 64.2 99 64.3 110 60.1 111 60.3
Secondary or more 75 48.7 62 43.4 54 35.8 55 35.7 73 39.9 73 39.7
Unknown 1 0.7 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Father’s education
Primary or less 35 22.7 30 21.0 41 27.2 51 33.1 46 25.1 51 27.7
Secondary or more 118 76.6 111 77.6 109 72.2 102 66.2 133 72.7 130 70.7
Unknown 1 0.7 2 1.4 1 0.7 1 0.7 4 2.2 3 1.6
Children in household
0 0 0.0 0 0.0 24 15.9 47 30.5 0 0.0 0 0.0
1–2 130 84.4 108 75.5 101 66.9 77 50.0 143 78.1 157 85.3
More than 2 24 15.6 35 24.5 26 17.2 30 19.5 34 18.6 24 13.0
Unknown 0 0.0 0 0.0 0 0.0 0 0.0 6 3.3 3 1.6
Wasting
No 108 70.1 116 81.1 148 80.9 129 70.1
Moderate 23 14.9 21 14.7 24 13.1 34 18.5
Severe 18 11.7 4 2.8 11 6.0 20 10.9
Unknown 5 3.3 2 1.4 0 0.0 1 0.5
Stunting
No 107 69.5 98 68.5 161 88.0 110 59.8
Moderate 21 13.6 28 19.6 16 8.7 39 21.2
Severe 23 14.9 15 10.5 6 3.3 34 18.5
Unknown 3 2.0 2 1.4 6 0.0 1 0.5
Routine OPV doses
0 32 20.8 16 11.2 41 22.4 39 21.2
1 18 11.7 13 9.1 14 7.7 8 4.4
2 8 5.2 21 14.7 18 9.8 17 9.2
3 42 27.3 36 25.2 20 10.9 14 7.6
4 51 33.1 51 35.7 90 49.2 103 56.0
Unknown 3 2.0 6 4.2 0 0.0 3 1.6
SIA OPV doses
0 28 18.2 5 3.5 28 15.3 9 4.9
1–3 51 33.1 20 14.0 58 31.7 16 8.7
4–6 61 39.6 30 21.0 68 37.2 27 14.7
7+ 10 6.5 79 55.2 26 14.2 125 67.9
Unknown 4 2.6 9 6.3 3 1.6 7 3.8
Total OPV doses
0 9 5.8 3 2.1 5 2.7 3 1.6
1–3 29 18.8 6 4.2 36 19.7 7 3.8
4–6 47 30.5 22 15.4 54 29.5 19 10.3
7+ 62 40.3 101 70.6 85 46.5 147 79.9
Unknown 7 4.6 11 7.7 3 1.6 8 4.4
Table 2
Poliovirus seroprevalence for different age groups, Kano, Nigeria, 2013.
Age group Number of subjects Type 1 (%) Type 2 (%) Type 3 (%)
6–9 months 154 58.4 41.6 51.9
36–47 months 143 93.0 84.6 87.4
5–9 years 151 94.0 92.7 89.4
10–14 years 154 96.1 92.9 89.0
Total 602 85.2 77.7 79.2
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lar for both the 6–9 month and 19–22 month age groups.
3.5. Risk factors
Table 3 shows the analysis of seroprevalence by demographic
characteristics and OPV doses for 6–9 month infants in the 2013and 2014 surveys. In both surveys, seroprevalence for all three ser-
otypes is associated with the number of routine doses received by
the participants (p = 0.021, <0.0001, 0.048 in 2013 and p < 0.001 for
all three types in 2014). Seroprevalence is associated with the total
number of OPV doses received for types 1 and 3 in the 2013 survey
(p = 0.002 and 0.008) and with all three types in 2014 (p < 0.001,
=0.002, <0.001 respectively). There is an association with the num-
ber of SIA OPV doses for types 1 and 3 in 2014 (p = 0.036 and
0.013). A similar trend is seen in 2013 but does not attain
significance.
In the 36–47 months age group in 2013, there was significant
association between seropositivity to all three serotypes with the
number of RI OPV doses received (p = 0.002, 0.02, and 0.02 for
types 1, 2 and 3, respectively) and for type 1 with the SIA doses
(p < 0.0001) and total OPV doses (p < 0.0001). For type 2, there
was also a significant association between mother’s educational
status and seropositivity (p = 0.03) possibly due to better routine
Table 3
Seroprevalence among subjects aged 6–9 months, by demographic or other attributes, Kano Metropolitan Area, Northern Nigeria, 2013, 2014.
2013 2014
No. of children PV1 PV2 PV3 No. of children P1 P2 P3
n % n % n % n % n % n %
Total 154 90 58.4 64 41.6 80 52.0 181 131 72.4 107 59.1 117 64.6
Gendera
Female 61 36 59.0 26 42.6 33 54.1 81 54 66.7 49 60.5 47 58.0
Male 93 54 58.1 38 40.9 47 50.5 100 77 77.0 58 58.0 70 70.0
Mother’s educationa
Primary or less 78 38 48.7 23 29.5 34 43.6 109 78 71.2 59 54.1 68 62.4
Secondary or more 75 51 68.0 40 53.3 46 61.3 72 53 73.6 48 66.7 49 68.1
Father’s educationa
Primary or less 35 18 51.4 7 20.0 14 40.0 46 31 67.4 23 50.0 28 60.9
Secondary or more 118 71 60.2 56 47.5 66 55.9 131 97 74.0 83 63.3 86 65.6
Children in householda
1–2 130 77 59.2 55 42.3 73 56.2 141 101 71.6 87 61.7 92 65.3
More than 2 24 13 54.2 9 37.5 7 29.2 34 25 73.5 16 47.1 23 67.7
Wastingb
No 108 62 57.4 45 41.7 55 50.9 146 101 69.2 82 56.1 93 63.7
Moderate 23 14 60.9 9 39.1 11 47.8 24 21 87.5 20 83.3 18 75.0
Severe 18 11 61.1 8 44.4 10 55.6 11 9 81.2 5 45.5 6 54.5
Stuntingb
No 107 69 64.5 48 44.9 61 57.0 159 113 71.1 94 59.1 105 66.0
Moderate 21 10 47.6 10 47.6 8 38.1 16 13 81.2 10 62.5 10 62.5
Severe 23 9 39.1 5 21.7 8 34.8 6 5 83.3 3 50.0 2 33.3
Routine OPV dosesb
0 32 14 43.8 3 9.4 12 37.5 41 18 43.9 11 26.8 13 31.7
1 18 9 50.0 4 22.2 9 50.0 13 9 69.2 6 46.2 10 76.9
2 8 4 50.0 3 37.5 4 50.0 18 16 88.9 11 61.1 13 72.2
3 42 27 64.3 21 50.0 22 52.4 20 14 70.0 13 65.0 13 65.0
4 51 34 66.7 32 62.8 31 60.8 89 74 83.1 66 74.2 68 76.4
SIA OPV dosesb
0 28 10 35.7 13 46.4 9 32.1 28 19 67.9 15 53.6 13 46.4
1–3 51 32 62.8 20 39.2 28 54.9 57 37 64.9 35 61.4 38 66.7
4–6 61 39 63.9 27 44.3 35 57.4 67 51 76.1 42 62.7 43 64.2
7+ 10 6 60.0 4 40.0 6 60.0 26 23 88.5 15 57.7 22 84.6
Total OPV dosesb
0 9 1 11.1 0 0.0 5 2 40.0 0 0.0
1–3 29 12 41.4 13 44.8 36 20 57.1 16 45.7
4–6 47 32 68.1 27 57.5 55 37 68.5 37 68.5
7+ 62 40 64.5 36 58.1 84 71 84.5 63 75.0
Covariates significantly associated with seropositivity at a = 0.05 are indicated in bold.
a Pearson Chi-square test.
b Cochrane-Armitage test for trend.
0%
20%
40%
60%
80%
100%
PV1 PV2 PV3
6-9 in 2013 19-22 in 2014
Fig. 1. Seroprevalence and 95% confidence intervals, by poliovirus serotype in
6–9 month old cohort in 2013 and 19–22 month old cohort in 2014.
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group in 2014, seropositivity is significantly associated with rou-
tine OPV doses for types 2 and 3 (p < 0.001 and p = 0.031), and with
SIA doses and total doses for types 1 and 3 (p < 0.001 for all tests),
possibly due to bOPV contributing heavily to SIA and total doses.
The logistic regression analysis is shown in Table 4. In 2013,
receiving at least one SIA dose was a significant predictor of
seropositivity for types 1 and 3: children who received at least
one SIA dose had nearly three-fold increased odds of being
seropositive for both types (type 1 OR = 2.77, 95% CI 1.08–7.49;
type 3 OR = 2.86, 95% CI 1.14–7.68). For type 2, RI doses were a sig-
nificant predictor of seropositivity: each additional dose increased
the odds of seropositivity by 2.22 (95% CI 1.66, 3.12). In 2014,
receiving an SIA dose was a significant predictor only for type 3,
but showed a similar three-fold increased odds of seropositivity
(OR = 3.20, 95% CI 1.32–7-76). However, RI doses were a significant
predictor for all three types, with each additional RI dose confer-
ring a 50–60% increase in odds of seropositivity (type 1
OR = 1.60, 95% CI 1.29–1.99; type 2 OR = 1.64, 95% CI 1.33–2.02;
type 3 OR = 1.49, 95% CI 1.21–1.83).
Table 4
Adjusted odds ratios and 95% confidence intervals for seroprevalence by RI and SIA doses received in children 6–9 months of age.
Comparison 2013 2014
Odds ratio 95% CI Type III p-value Odds ratio 95% CI Type III p-value
Type 1
RI dose (continuous) Each additional dose 1.08 [0.85, 1.37] 0.523 1.60 [1.29, 1.99] <0.001
Any campaign dose 1+ vs. 0 SIA doses 2.77 [1.08, 7.49] 0.037 1.55 [0.60, 4.00] 0.366
Type 2a
RI dose (continuous) Each additional dose 2.22 [1.66, 3.12] <0.001 1.64 [1.33, 2.02] <0.001
Type 3
RI dose (continuous) Each additional dose 1.22 [0.98, 1.54] 0.082 1.49 [1.21, 1.83] <0.001
Any campaign dose 1+ vs. 0 SIA doses 2.86 [1.14, 7.68] 0.030 3.20 [1.32, 7.76] 0.01
a Analysis of campaign doses was excluded for Type 2, as children in the 6–9 month age group only received Type 2 containing vaccine through routine immunization in
2013 (all relevant campaign doses were bOPV), and were exposed to at most one tOPV campaign dose in 2014.
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cant predictor of seropositivity. There is no consistent relationship
between seropositivity and socioeconomic and nutritional param-
eters across the two surveys.
4. Discussion
These seroprevalence surveys document the immunity profiles
in the historical polio reservoir area of northern Nigeria over a cru-
cial period before and after the interruption of poliovirus transmis-
sion. Our surveys provide several new insights.
The 2013 survey showed that seroprevalence was unexpectedly
low in the 6–9 months age group. Nevertheless, we do believe that
low seroprevalence in this age group had reflected recent program-
matic gaps. Attacks on health care workers had resulted in cancel-
lation of the March 2013 SIA campaign in Kano and could
potentially have affected the quality of the subsequent campaigns.
The seroprevalence in 36–47 month children was high and there
were only minor gains in seroprevalence levels in the older age
groups of 5–9 and 10–14 years. Nevertheless, both in 6–9 month
and 36–47 month age groups, an increasing number of OPV doses
resulted in increasing levels of seroprevalence. This confirms the
effectiveness of OPV in inducing immunity in these populations.
While seroprevalence recovered to an extent in 6–9 month age
group by 2014, it remained below 75% for all three serotypes. There
was significant improvement in the 19–22 month age group over
the corresponding 6–9 month group of 2013. Besides age and num-
ber of vaccine doses, seroprevalence has a reasonable consistent
relationship with vaccine types used in routine and supplementary
immunization, like impact of bOPV SIA doses on type 1 and 3
immunity and that of tOPV RI doses on type 2. Continued low sero-
prevalence to type 2 remains a key concern and indicates less
exposure to type 2 containing vaccines. It seems improvement in
program quality and incremental gains in immunity helped Kano
achieve polio free status and no wild virus or VDPV has been
reported from the state in 2015 and till date in 2016.
While the exact threshold immunity to interrupt transmission
is not known for northern Nigeria, seroprevalence in Kano, Nigeria
is well below the levels reported from Egypt and India (98–99%) in
the final stages of eradication [21,22]. Although such extremely
high immunity levels were probably not needed in the Nigerian
context to interrupt transmission, the data does suggest that fur-
ther increase in vaccination coverage in both routine and SIAs must
be achieved to improve and sustain high immunity levels.
Our study had limitations, mainly associated with facility-based
design. This study was not population-based and thus the results
are not generalizable to the entire population. Nevertheless, our
survey demonstrated that in the study population who accessed
care in a general government hospital, the seroprevalence rates
were suboptimal. It is probably safe to assume that the seropreva-
lence levels could be even lower in other populations withoutaccess to health services. For data collection, we had to rely on par-
ental recall for a number of variables, including vaccination his-
tory, maternal education, and age. In addition, the study design
and sample size were not meant to be able to assess differences
in small sub-populations.
Though the community-level acceptance for vaccination was
variable in the area, we observed a good parental response for par-
ticipation in the seroprevalence survey in the health facility-based
surveys. We plan to repeat seroprevalence surveys in Kano Nigeria
to monitor the population immunity and measure the impact of
tOPV-bOPV switch and introduction of IPV in the routine immu-
nization program.Funding
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